Renal Cancer Clinical Trial
Official title:
An Open-Label Phase I Study of the Safety of Perifosine in Combination With Sunitinib Malate for Patients With Advanced Cancers
This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine and sunitinib malate will be determined. In part 2, with the MTD as a starting point, a group of patients will be accrued with the goal of ensuring that they will be able to tolerate at least two courses of therapy, which would make them evaluable for response in a Phase II study.
This study is a Phase I trial in two parts. In part 1, an MTD to the combination of
perifosine and sunitinib malate will be determined. In some previous trials with perifosine
and other biologic agents, doses determined in Phase I studies are not as well tolerated in
larger groups of patients when response is an endpoint. Thus in part 2, with the MTD as a
starting point, a group of patients will be accrued with the goal of ensuring that they will
be able to tolerate at least two courses of therapy, which would make them evaluable for
response in a Phase II study. As a secondary endpoint, the effects of the combination of
perifosine and sunitinib malate will be evaluated for response rate and time to progression.
The pharmacokinetics of the combination of the study drugs will be measured.
For the purposes of this study, one cycle of therapy will be defined as 6 weeks. Patients
will take one 50 mg tablet of perifosine one to three times a day and sunitinib malate once
a day for 4 out of 6 weeks. Patients may need anti-emetics and/or anti-diarrheals. Patients
will be evaluated for progression or response at 12-week intervals.
Patients who experience toxicity may continue on treatment with doses delayed or reduced.
All patients should continue therapy unless disease progression is documented on two
occasions at least four weeks apart.
Part 1 of this Phase I study will accrue from six to 24 patients depending on the number of
dose levels evaluated. Up to six patients will be treated at each dose level. A dose
limiting toxicity (DLT) will be defined as:
- Grade 3 or greater non-hematologic toxicity
- Grade 4 hematologic toxicity
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT00531284 -
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05842044 -
NSAID Use After Robotic Partial Nephrectomy
|
Phase 2 | |
Recruiting |
NCT05387863 -
Decision Aid (DA) for Renal Patients
|
N/A | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Withdrawn |
NCT03390413 -
Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer
|
N/A | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03203473 -
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
|
Phase 2 | |
Suspended |
NCT04115254 -
Stereotactic Magnetic Resonance Guided Radiation Therapy
|
N/A | |
Enrolling by invitation |
NCT02609269 -
Decipher Genomics Resource for Intelligent Discovery
|
||
Completed |
NCT01444456 -
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
|
N/A | |
Terminated |
NCT01453595 -
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
|
Phase 1/Phase 2 | |
Completed |
NCT02811250 -
Stereotactic Radiotherapy for Renal Cancers
|
N/A | |
Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT00458536 -
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
|
Phase 1/Phase 2 | |
Recruiting |
NCT03693014 -
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
|
Phase 2 | |
Completed |
NCT00418496 -
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT06051162 -
HPI Effect in Robotic Urological Surgery on AKI
|
N/A |